Metsera, Inc. (MTSR)
MTSR Stock Price Chart
Explore Metsera, Inc. interactive price chart. Choose custom timeframes to analyze MTSR price movements and trends.
MTSR Company Profile
Discover essential business fundamentals and corporate details for Metsera, Inc. (MTSR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2025
Employees
93.00
Website
https://metsera.comCEO
Christopher Whitten Bernard
Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
MTSR Financial Timeline
Browse a chronological timeline of Metsera, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Oct 2025
EPS estimate is -$0.56.
Earnings released on 28 Jul 2025
EPS came in at -$0.66 falling short of the estimated -$0.66 by -0.29%.
Earnings released on 12 May 2025
EPS came in at -$1.03 falling short of the estimated -$0.85 by -21.18%.
Earnings released on 26 Mar 2025
EPS came in at -$3.52 falling short of the estimated -$0.80 by -340.00%.
Earnings released on 26 Feb 2025
MTSR Stock Performance
Access detailed MTSR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.